Results 101 to 110 of about 21,748 (299)
Understanding the Incretin Effect [PDF]
The Journal of Clinical Endocrinology & Metabolism, 2011 It is well known that the incretin effect contributes as much as half of the insulin secretory response to oral glucose load and that this effect is reduced along with worsening glucose tolerance in those with type 2 diabetes. Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the two primary incretin hormones secreted from ...
openaire +2 more sources
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aim Eloralintide (LY3841136) is a potent, long‐acting selective amylin receptor agonist currently under development for the treatment of obesity with once‐weekly subcutaneous dosing. Materials and Methods This 12‐week Phase 1, randomised, placebo‐controlled, participant‐ and investigator‐blinded, multiple ascending dose study evaluated the ...
Shobha Bhattachar +8 more
wiley +1 more source
Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. [PDF]
, 2019 Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions ...
Akiba, Yasutada +2 more
core
Incretins (GLP1 r agonists and dual, triple agonists) and the liver.
Journal of Hepatology, 2023 P. Newsome, P. Ambery
semanticscholar +1 more source
Regulation of Insulin Secretion Through Long‐Chain Fatty Acid Receptors
iNew Medicine, EarlyView.
Stefan Offermanns
wiley +1 more source
Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims Imeglimin is a novel oral hypoglycemic agent approved for the treatment of type 2 diabetes in Japan, with dual actions to enhance insulin secretion and improve insulin sensitivity, suggested by preclinical evidence. However, the effect of imeglimin on tissue‐specific insulin sensitivity and glucose kinetics using glucose tracers is ...
Tsubasa Tajima +10 more
wiley +1 more source
Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies [PDF]
Diabetes & Metabolism JournalGlucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as blockbuster drugs for treating metabolic diseases. Glucagon-like peptide-1 (GLP-1) plays a pivotal role in glucose homeostasis by enhancing insulin secretion, suppressing glucagon ...
Joon Seok Park +2 more
doaj +1 more source
Direct Autocrine Action of Insulin on β-Cells: Does It Make Physiological Sense? [PDF]
, 2014 In recent years there has been a growing interest in the possibility of a direct autocrine effect of insulin on the pancreatic β-cell. Indeed, there have been numerous intriguing articles and several eloquent reviews written on the subject (1–3); however,
Kahn, Steven E. +3 more
core +1 more source
Lipotoxicity impairs incretin signalling [PDF]
Diabetologia, 2012 The incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic peptide are secreted by enteroendocrine cells and augment glucose-induced insulin secretion in response to food ingestion in a glucose-dependent manner. This mechanism forms the basis for incretin-based therapies in type 2 diabetes.
openaire +2 more sources
Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques, 2015 Introduction The hormonal brain-gut axis is a crucial element in appetite control and the response to surgical treatment for super obesity. However, mechanisms underlying the metabolic response to surgical treatment for morbid obesity are still not ...
P. Major +9 more
semanticscholar +1 more source